In summary, the surface protein profile of EVs from breast cancer patients suggested that EVs with the typical EV markers CD9, CD63 and CD81 were of cancer cell origin, as well as released by antigen-presenting cells and platelets. This evidence concerns the gene CD9 and cancer.